- Addex to Present at Bio€quity Europe 2024
- Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
- Addex to Present at the Swiss Biotech Day 2024
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
- Addex to Present at the Bio-Europe Spring 2024 Conference
- Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
- Addex to Present at the Swiss Equities Baader Conference
- Addex to Present at Biotech Showcase™ 2024
More ▼
Key statistics
On Friday, Addex Therapeutics Ltd (ADXN:SWX) closed at 0.073, 101.66% above the 52 week low of 0.0362 set on Nov 29, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0732 |
---|---|
High | 0.0732 |
Low | 0.07 |
Bid | 0.0714 |
Offer | 0.073 |
Previous close | 0.0734 |
Average volume | 2.08m |
---|---|
Shares outstanding | 184.35m |
Free float | 153.41m |
P/E (TTM) | -- |
Market cap | 13.46m CHF |
EPS (TTM) | -0.1433 CHF |
Data delayed at least 15 minutes, as of May 10 2024 16:31 BST.
More ▼